Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (1051-1060 of 1,298) with videos related to

Pageof 130
Sort By:
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Journal of Translational Medicine|December 16, 2018
Implementing a comprehensive translational oncology platform: from molecular testing to actionabilityZahi I Mitri, Swapnil Parmar, Brett Johnson, et al.
Nature Genetics|November 21, 2023
Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevanceJunpeng Fan, Funian Lu, Tianyu Qin, et al.
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Oncogene|July 8, 2014
Autophagy mediates HIF2α degradation and suppresses renal tumorigenesisX-D Liu, J Yao, D N Tripathi, et al.
Cancer Cell|August 14, 2014
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorGang Lu, Qing Zhang, Ying Huang, et al.
NPJ Breast Cancer|December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activityJ K Litton, M Scoggins, D L Ramirez, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 16, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal WomenCarol J Fabian, Bruce F Kimler, Teresa A Phillips, et al.
International Journal of Cancer|November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancerAndrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Molecular Oncology|May 3, 2020
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasisRomela Irene Ramos, Matias A Bustos, Jinfeng Wu, et al.
Pageof 130

Showing results (1051-1060 of 1,298) with videos related to

Sort By:
Pageof 130
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Journal of Translational Medicine|December 16, 2018
Implementing a comprehensive translational oncology platform: from molecular testing to actionabilityZahi I Mitri, Swapnil Parmar, Brett Johnson, et al.
Nature Genetics|November 21, 2023
Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevanceJunpeng Fan, Funian Lu, Tianyu Qin, et al.
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Oncogene|July 8, 2014
Autophagy mediates HIF2α degradation and suppresses renal tumorigenesisX-D Liu, J Yao, D N Tripathi, et al.
Cancer Cell|August 14, 2014
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorGang Lu, Qing Zhang, Ying Huang, et al.
NPJ Breast Cancer|December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activityJ K Litton, M Scoggins, D L Ramirez, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 16, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal WomenCarol J Fabian, Bruce F Kimler, Teresa A Phillips, et al.
International Journal of Cancer|November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancerAndrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Molecular Oncology|May 3, 2020
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasisRomela Irene Ramos, Matias A Bustos, Jinfeng Wu, et al.
Pageof 130